Aytu BioPharma, Inc. (NASDAQ:AYTU) CEO Joshua R. Disbrow Acquires 15,000 Shares

Aytu BioPharma, Inc. (NASDAQ:AYTU) CEO Joshua R. Disbrow acquired 15,000 shares of the business’s stock in a transaction dated Friday, February 28th. The shares were acquired at an average cost of $1.30 per share, with a total value of $19,500.00. Following the acquisition, the chief executive officer now directly owns 86,591 shares of the company’s stock, valued at $112,568.30. This represents a 20.95 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Aytu BioPharma Stock Performance

NASDAQ:AYTU opened at $1.26 on Tuesday. The business has a 50 day moving average of $1.57 and a 200 day moving average of $1.89. The company has a market capitalization of $7.77 million, a price-to-earnings ratio of -0.87 and a beta of -1.45. Aytu BioPharma, Inc. has a 1-year low of $1.23 and a 1-year high of $3.45. The company has a debt-to-equity ratio of 0.32, a current ratio of 0.98 and a quick ratio of 0.81.

Aytu BioPharma (NASDAQ:AYTU) last released its earnings results on Wednesday, February 12th. The company reported ($0.28) earnings per share for the quarter. Aytu BioPharma had a negative return on equity of 19.30% and a negative net margin of 7.62%.

Institutional Trading of Aytu BioPharma

An institutional investor recently raised its position in Aytu BioPharma stock. Stonepine Capital Management LLC increased its position in Aytu BioPharma, Inc. (NASDAQ:AYTU) by 6.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 500,958 shares of the company’s stock after buying an additional 28,489 shares during the quarter. Aytu BioPharma accounts for 0.7% of Stonepine Capital Management LLC’s portfolio, making the stock its 25th largest position. Stonepine Capital Management LLC owned about 8.15% of Aytu BioPharma worth $1,177,000 at the end of the most recent quarter. 33.49% of the stock is owned by hedge funds and other institutional investors.

Aytu BioPharma Company Profile

Aytu Biopharma, Inc is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers.